Cryoport (CYRX) Investor presentation summary

Strategic positioning and market overview

• Positioned as a critical infrastructure provider for the cell and gene therapy (C&GT) industry, enabling efficient production, innovation, and global scalability through integrated supply chain solutions.

• Supports 17 commercial C&GT therapies and 691 active clinical trials, with a global platform spanning 50+ facilities in 17 countries and over 3,000 clients.

• Offers a comprehensive suite of services including temperature-controlled logistics, biostorage, consulting, and regulatory support, with proprietary technologies for traceability and compliance.

• Maintains a strong ESG and sustainability framework focused on operational efficiency, employee well-being, responsible innovation, and ethical governance.

Financial performance and outlook

• Q3 2024 revenue reached $56.7M, with full-year 2024 revenue guidance of $225–$235M and $273M in cash and short-term investments.

• Life Sciences Services revenue grew 9% year-over-year in Q3 2024, while Life Sciences Products revenue declined 14% for the same period.

• Reported a net loss attributable to common stockholders of $1.2M for Q3 2024, with adjusted EBITDA at $(2.4)M, reflecting ongoing cost reduction and capital realignment initiatives.

• Expects to return to positive adjusted EBITDA during 2025 as cost measures are completed.

Operational capabilities and innovation

• Proprietary shipper fleet and logistics management platform (Cryoportal® 2 and Smartpak II®) provide real-time monitoring and traceability for chain of custody, condition, identity, and compliance.

• IntegriCell™ platform standardizes cryopreservation and distribution for starting materials, reducing risks and costs while improving quality.

• MVE Biological Solutions, a subsidiary, is a global leader in cryogenic systems, with FDA-registered facilities and innovative freezers for secure storage and transport.

• CRYOGENE operates one of the largest GMP-compliant biorepositories in the U.S., with exclusive partnerships and expansion plans.